MEDICINES360 - Key Persons

Job Titles:

• Chief Executive Officer

Andrea Olariu, MD, PhD is Chief Executive Officer (CEO) of Medicines360. Since joining the company in 2010, Dr. Olariu has held several key roles for the organization. During her time as Chief Operations Officer (COO), Dr. Olariu oversaw Clinical/Medical and Regulatory Affairs, Product Development, and the Quality Department. Prior to her appointment as CEO for Medicines360, Dr. Olariu served as CEO for CuraePharma360. In her steady tenure at Medicines360, Dr. Olariu led the development, approval and product expansion strategy for the company's hormonal IUD. Dr. Olariu has extensive experience designing and conducting clinical trials from proof-of-concept to large pivotal Phase 3 studies. Before joining Medicines360, Dr. Olariu developed and implemented clinical/medical and regulatory strategies for several medical devices that received approval in the United States, Canada, and the European Union. Prior to moving to the US, Dr. Olariu spent over 15 years working in academia, as an Associate Professor of Dermatology at the University of Szeged in Szeged, Hungary and as a Senior Lecturer of Immunology at the Victor Babes University of Medicine and Pharmacy Timisoara, Romania. Dr. Olariu has authored over 40 peer-reviewed medical publications, is the recipient of several academic honors, and has spoken at national and international conferences.

Job Titles:

• Vice President
• Vice President, Commercial and Business Development

Ann Deren-Lewis is our Vice President of Commercial and Business Development with over 25 years of experience in the pharmaceutical, medical device, diagnostics, over-the-counter (OTC), and skincare markets, leading commercial functions including marketing, sales, market access, key opinion leader management, and business development. Before joining Medicines360, Ms. Deren-Lewis was the Chief Commercial Officer of Mindera Health and oversaw commercial operations at the company, which specializes in precision medicine for chronic dermatological conditions. Prior to Mindera Health, she held the position of Senior Vice President of Corporate Development for Zerigo Health, where she built a sales, marketing, and Care Partner team for commercialization. In 2015, she became the Founder and Principal of Two Blue Consulting, where she offered strategic and operational expertise to companies of all sizes, including Johnson and Johnson, Pfizer, Castle Biosciences, Vibrant Gastro, Dermascope, Ellis Day Skin Science, Nanopass, Celluma, and Vitality Institute, among others. Prior to founding her consulting company, Ms. Deren-Lewis held senior executive positions with ChromaDex, Vertos Medical, Merz, Stiefel (GSK), Johnson and Johnson, Genentech, and Amgen. Ms. Deren-Lewis holds an MBA from Duke University, Fuqua School of Business and a Bachelor of Science degree in Accounting from the University of North Carolina-Wilmington.

Job Titles:

• Member of the Board of Directors
• Managing Director at Hall Capital Partners LLC
• Member of the Board of Directors of Both the UCSF Foundation Investment Company

Ann Barber is a Managing Director at Hall Capital Partners LLC in the Public Equity group, responsible for research, identification, due diligence, and monitoring of long-only public equity investments and long-short equity hedge funds. She is also a Portfolio Manager for several family, and endowment and foundation clients. Barber is also a member of Medicines360's Investment Review Committee. Prior to joining the firm in 2006, Ms. Barber spent several years at Lazard Asset Management in New York where she consulted on a number of strategic projects, and researched Japanese financial stocks. Previously, she was a Senior Research Analyst covering health care equities at Montgomery Asset Management, Credit Suisse-First Boston, Cowen & Co., and Prudential Securities. She began her financial career at Prudential Securities in investment banking, prior to transferring into the equity research emerging analyst program. Ms. Barber is a member of the Board of Directors of both the UCSF Foundation Investment Company and Medicines360, a global non-profit women's health pharmaceutical company. She also serves on the Investment Committee for the Marin Community Foundation. Previously, Ms. Barber served on the Investment Committee for both the San Francisco Day School and Gateway Schools in San Francisco, and was a member of the Bay Area Board of Directors for Reading Partners, a non-profit devoted to promoting literacy in public schools. Ms. Barber graduated with honors from the University of Wisconsin at Madison with a B.A. in Economics, International Relations and Spanish. She also earned an M.A. from the School of Advanced International Studies (SAIS) of The Johns Hopkins University, and an M.B.A. from the Wharton School of the University of Pennsylvania.

Job Titles:

• Chief Financial Officer
• Senior Financial Executive

Brad Luke is a senior financial executive with over twenty years of experience in finance and accounting for the healthcare, technology, and non-profit industries. Before joining Medicines360, Mr. Luke was the CFO at Archimedes, Inc., a for-profit healthcare analytics company which was owned by Kaiser Permanente and partially funded by the Robert Wood Johnson Foundation. Previously, Mr. Luke was VP/Controller at Arcadian Health Plan, a start-up HMO in Oakland, and before that the Controller at The Tides Center, a non-profit organization in the Presidio of San Francisco. Mr. Luke's financial experience in the non-profit sector as well as public and private for-profit companies has given him exceptional business knowledge coupled with the ability to address core business issues. Mr. Luke has experience in Mergers and Acquisitions as well as venture-backed funding. He also possess experience driving key finance and accounting initiatives through cross functional partnerships and experience in driving process improvements resulting in more efficient operations. Mr. Luke received his MBA and BA in Business from California State University, Fullerton.

Job Titles:

• General Counsel

Cynthia Hu has over 15 years of experience as a biopharmaceutical executive serving publicly listed biotechnology companies, including roles as Chief Legal Officer, General Counsel, Chief Operating Officer, and Chief Financial Officer, where she was responsible for legal, governance and compliance, and oversaw business development, fundraising, and investor communications. Prior to entering industry, Cynthia practiced for more than 10 years as a corporate securities attorney in private law firm practices in NYC and Washington, DC, focused on M&A, public offerings and securities-related transactions. Cynthia is an advisor to a healthcare-dedicated venture capital firm based in the Bay Area, and in 2002, co-founded Women in Bio, Inc., a nonprofit, volunteer-led national professional organization currently with 14 chapters and 3,500+ members across the country. Cynthia holds a bachelor's degree from New York University and a juris doctorate degree from Rutgers University.

Job Titles:

• Professor of Bioengineering

Dr. Leslie Z. Benet is a Professor of Bioengineering and Therapeutic Sciences, and Pharmaceutical Chemistry at the University of California, San Francisco (UCSF), and is an internationally recognized authority on drug development. He is former Chair of the Department at UCSF (1978-1998), and currently lectures at UCSF on drug development and the operation of the FDA. Dr. Benet has founded four start-up pharmaceutical companies and holds twelve US patents on pharmaceutical compounds. He has received eight honorary doctorates. His research interests include pharmacokinetics, biopharmaceutics, drug delivery and pharmacodynamics, which has produced more than 540 publications and seven books. Dr. Benet is listed by Thompson Reuters as one of most highly cited pharmacologists worldwide in both the 2001 and 2014 compilations, with his published peer-reviewed papers cited more than 22,000 times. He is a Fellow of the Academy of Pharmaceutical Sciences and Research, the American Association of Pharmaceutical Scientists (AAPS), the American College of Clinical Pharmacology and the American Association for the Advancement of Science (AAAS). He is past chair of the International Pharmaceutical Federation, and is a member of the Institute of Medicine (IOM) of the National Academy of Sciences. Dr. Benet served as a member of the FDA Generic Drugs Advisory Committee and the FDA Science Board, as Chair of the CBER subcommittee of the FDA Science Board that delivered its review of science at the FDA in December 2007 and an outside member of the FDA CDER Director and Office of Generic Drugs Deputy Director search committees. Dr. Benet served on the IOM Forum on Drug Discovery, Development and Translation, the Biodefense Standing Committee of the Department of Defense and on the Boards of Directors of the American Foundation for Pharmaceutical Education, Impax Laboratories, and Institute for OneWorld Health. He is a Scientific Advisory Board Member and/or Consultant for more than 30 pharmaceutical and biotechnology companies.

With over a decade of pharmaceutical development experience, Dr. Garner brings expansive knowledge in regulatory and clinical affairs, and a deep commitment to increasing access to medicines for women globally. As a trained OB/GYN, Dr. Garner currently serves as Chief Medical Officer at ObsEva, where she focuses on addressing serious unmet needs in women's health by providing strategic leadership on the company's overall development strategy. Prior to joining ObsEva, Dr. Garner served as the Chief Medical Officer at Agile Therapeutics, where she successfully led the company's clinical development, regulatory, and medical affairs strategies. During her time there, she was instrumental in obtaining the Food and Drug Administration (FDA) approval of Twirla®️, Agile's low-dose contraceptive patch. Dr. Garner's past clinical roles included leading the global Phase 3 endometriosis clinical development program for Orilissa®️ at Abbott Laboratories and working on FDA submissions for the HPV vaccine, Gardasil®️. Her commitment to advocating for progress in women's health has driven her to volunteer on several nonprofit boards including the American Medical Women's Association (AMWA) the Drug Information Association (DIA), and CorStone, a global nonprofit focused on resilience training for marginalized youth. Dr. Garner holds a medical degree from Harvard Medical School and a master's degree in public health from Harvard's T.H. Chan School of Public Health with a bachelor's degree from Mount Holyoke College in Massachusetts.

Job Titles:

• Co - Chair of the Board of Directors of Repligen Corporation

Karen A. Dawes (MBA, Harvard University - concentration in marketing and corporate strategy; MA & BA, Simmons College - English and Communications) is the President and Founder of Knowledgeable Decisions, LLC. With 20+ years of commercial and executive management experience in the BioPharma industry, Karen brings to clients a valuable and unique combination of competencies. Karen's industry experience began with 10 years of commercial and executive management at Pfizer, where she gained increasing responsibility in product management, development, and strategy leading to her position as Vice-President, Marketing, Pratt Division. Karen then moved to biotech pioneer Genetics Institute (GI), where, as Chief Commercial Officer, she built the company's initial commercial operations including strategic and operational marketing, sales, medical affairs, public relations, and market research. At GI she and her team launched the company's first two products - BeneFix for Factor IX replacement in hemophilia and Neumega for the treatment of thrombocytopenia in cancer patients. When GI was acquired by Wyeth, Karen moved to the new parent company as Senior Vice-President, Global Strategic Marketing with responsibility for strategic product development and global marketing. In 1998, Karen moved to Bayer Corporation as Division Head for the company's $2 billion U.S. Pharmaceuticals Division. She founded Knowledgeable Decisions in 2003. Throughout her career, Karen has been a key player in the successful development, launch and marketing of products in the Cardiovascular, Metabolic, Infectious Disease, CNS, Oncology and Women's and Men's Health areas, including five products that each exceeded sales of $1 billion dollars. Karen is Co-Chair of the Board of Directors of Repligen Corporation, and a member of the Boards of Directors of Depomed, Inc., Inspiration Biopharmaceuticals, and Seaside Therapeutics. She is also a founder of The ProPharmex Group, a consortium of independent consultants who focus on strategic development and commercialization in BioPharma. Karen is a frequent speaker to academic and industry groups.

Job Titles:

• Chairman
• Member of the Board of Directors
• President and CEO of Public Health Solutions

Lisa David is the President and CEO of Public Health Solutions, an organization working to improve health outcomes in New York City's most vulnerable communities. Ms. David comes to Medicines360 with significant experience in the reproductive health community. Previously, she served as Executive Vice President and Chief Operating Officer of the Planned Parenthood Federation of America. At Planned Parenthood she was responsible for health care strategy and support for Planned Parenthood's affiliate health care operations both across the United States, as well as in Africa and South America. In addition, she led the HR and Finance functions for the organization. Over the past 6 years Ms. David led initiatives to improve operational efficiency, increase participation in managed care programs, migrate to electronic health records, develop innovative health care delivery models using on line health services, improve patient service and engagement, and expand clinical research and clinical quality programs. Over her six years tenure, as a result of successful programmatic fundraising initiatives, the scope of services to support affiliates doubled. Prior to joining Planned Parenthood, Ms. David was the Vice Chair Administration and Department Administrator for the Department of Obstetrics and Gynecology at the Columbia College of Physicians and Surgeons and New York Presbyterian Hospital. During her 5 years tenure she led the department through a financial turnaround and helped to build the quality and scope of subspecialty clinical programs. Ms. David was a health care and women's health strategy consultant for 17 years at APM, CSC Healthcare Consulting, Women's Health Management Solutions, and Chartis. She has a BS in Biology from Barnard, and an MBA from Wharton.

Job Titles:

• Vice President of Strategic Development

Margot Fahnestock is the Vice President of Strategic Development for Medicines360. In her role, she leads mission-based program development, impact measurement, and resource mobilization. As a philanthropy and policy expert in family planning and reproductive health, Margot formerly served as a Program Officer at the William and Flora Hewlett Foundation, responsible for making grants to reduce unintended pregnancies and improve reproductive health and rights in sub-Saharan Africa. She was a founding member and catalyst for the Ouagadougou Partnership, which has mobilized more than $250 million in additional funding for family planning in Francophone West Africa. Prior to Hewlett Margot was a policy analyst and project manager at Futures Group, providing technical and managerial oversight for family planning, HIV/AIDS, and malaria policy programs. Margot served two years as a U.S. Peace Corps volunteer teaching English at a secondary school in Mali, West Africa. She has a bachelor's degree in English from the University of California, Los Angeles and master's in public policy from the University of Chicago.

Job Titles:

• Senior Vice President, Quality and Product Safety

Mark Busch, PhD brings over twenty years of experience in QA/QC, analytical, and regulatory support of GXP operations. Prior to joining Medicines360, he held a number of senior level Quality positions including VP of QA at NeurogesX. He also brings with him extensive experience as a senior Quality leader from his tenure at firms like Geron, VaxGen, InterMune, and Scios. He also led a successful pharmaceutical consulting business. As a Quality executive, Dr. Busch has expertise in developing and implementing Quality systems, SOPs, and audits, as well as reviews of manufacturing and technical documentation for compliance assessment and remediation. In addition, Dr. Busch has published several peer reviewed articles. Dr. Busch holds a PhD in Biological Chemistry from Indiana University and performed post-doctoral research at Carnegie Mellon University.

Michael C. Dorsey has had a successful 20-year career as an investment banker to technology companies, and for the last 14 years has been a successful venture capitalist, having co-founded and run the most successful double bottom line venture capital fund, the Bay Area Equity Fund, which invested in Tesla Motors, Solar City, Pandora, Revolution Foods, Labcyte, Peninsula Pharmaceuticals, Five Prime Therapeutics, CareDx, and others. He also serves as a Director of Revolution Foods and Habitat for Humanity of the Greater Bay Area, and the Parents Advisory board of Stanford University and the Impact Investing Initiative of the Fuqua School of Business at Duke University. He is married to Susan Ford Dorsey, lives in Woodside CA, and has three adult children.

Job Titles:

• Vice President, Product Development

Robert "Rob" Deckman brings over twenty years of experience in the medical device and pharmaceutical industries, working in the areas of design, manufacturing, and project management from product concept through market release. Prior to joining Medicines360, Mr. Deckman was an independent consultant working with startup companies across the San Francisco Bay Area and throughout the United States. Throughout his career, he has held R&D and manufacturing positions at startups and larger, well-established companies. Mr. Deckman led the development of Medicines360's first medical device design and is a named inventor on over twenty US and international patent applications. Mr. Deckman graduated from San Jose State University with a BS in Mechanical Engineering. He is currently working on an MS in Engineering at Santa Clara University.

Job Titles:

• Chief Executive Officer
• Director of the Women 's Health Research Institute

Tina Raine-Bennett, MD, MPH, is CEO of Medicines360. Previously, she served as a senior research scientist at the Kaiser Permanente Northern California Division of Research and the research director of the Women's Health Research Institute. She is a Board-Certified Obstetrician Gynecologist who received her medical training at the University of California, San Diego, and post-graduate residency training and MPH at the University of Washington in Seattle, where she also completed a Robert Wood Johnson Clinical Scholars Fellowship. She was also senior staff physician at Kaiser Permanente and has a special interest in family planning and adolescent reproductive health. As the director of the Women's Health Research Institute, Dr. Raine-Bennett focused on expanding research on women's health within the Division and translating women's health research into clinical practice and policy within the Ob/Gyn departments in Northern California. She also promoted the involvement of clinicians in research designed to improve the health outcomes and healthcare experiences of women at Kaiser Permanente and women in general. Prior to Kaiser Permanente, Dr. Raine-Bennett was a professor in the Department of Obstetrics, Gynecology, and Reproductive Sciences at University of California, San Francisco (UCSF). She was based at San Francisco General Hospital where she was also the medical director of the New Generation Health Center, a UCSF affiliate site that provides community-based reproductive health services. Dr. Raine-Bennett's research has focused on contraceptive methods and on elucidating factors that influence contraceptive choice and continuation, and she was principal investigator on NIH grants to assess hormonal contraceptive use predictors and develop interventions to improve contraceptive access. Her past and current research on emergency contraception has focused on the safety of making emergency contraception more accessible and she conducted a pivotal clinical trial to make emergency contraception available to teens without a prescription. She served on the editorial board of Obstetrics and Gynecology and has over 100 peer-reviewed publications. She was the Treasurer of the Board of Directors for the Society of Family Planning and Society of Family Planning Research Fund. She has also served as an examiner for the American Board of Obstetrics and Gynecology, and on national committees for the American College of Obstetrics and Gynecology and the National Medical Board of Planned Parenthood Federation of America.